We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Patients sought for first-in-human trial of pancreatic cancer treatment

A first-in-human clinical trial testing RMC-5127, an experimental treatment for people with pancreatic cancer and other cancers marked by a specific genetic mutation called RAS G12V, is now recruiting participants in the U.S. The Phase 1 trial (NCT07349537) is open to...
Read More

Experimental immunotherapy extends survival in aggressive brain cancer trial

The majority of patients with recurrent glioblastoma remain alive following treatment with an experimental immune-modulating combination, according to a clinical trial update from Immunitybio. The data highlights a potential shift in managing a disease where “immune...
Read More

Adding relacorilant to chemo shown to boost survival in ovarian cancer trial

Treatment with relacorilant plus standard chemotherapy was shown in a clinical trial to significantly improve survival compared with chemo alone for people with hard-to-treat ovarian cancer. That’s according to new data announced by relacorilant’s developer Corcept...
Read More

Source: Pharmacy Times articles Post Content Read More
Read More

Trial of myeloma therapy KLN-1010 gets FDA green light to expand to US

A clinical trial in Australia that’s testing the genetic therapy KLN-1010 in people with hard-to-treat multiple myeloma has won regulatory approval to add new study sites in the U.S. The Phase 1 study, dubbed inMMyCAR (NCT07075185), will soon start enrolling patients...
Read More

Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry

Source: Myeloma : nature.com subject feeds Post Content Read More
Read More
Latest Data

Latest Publications

Epidemiology of Monoclonal Gammopathies in Sub-Saharan Africa: A Systematic Review and Meta-Analysis of MGUS and Multiple Myeloma

Trop Med Int Health. 2026 Jan 28. doi: 10.1111/tmi.70066. Online ahead of print. ABSTRACT...
Read More

Systematic review of frailty, functional status & comorbidities in older adults with multiple myeloma undergoing high dose therapy & autologous stem cell transplant

J Geriatr Oncol. 2026 Jan 26;17(2):102846. doi: 10.1016/j.jgo.2025.102846. Online ahead of print....
Read More

Efficacy and Safety of Newly Diagnosed Multiple Myeloma Combination Therapies: A Systematic Review Integrating Network Meta-Analysis and Real-World Vigilance Study

Pharmaceuticals (Basel). 2025 Dec 21;19(1):18. doi: 10.3390/ph19010018. ABSTRACT Background:...
Read More

To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies

Front Immunol. 2026 Jan 12;16:1722579. doi: 10.3389/fimmu.2025.1722579. eCollection 2025. ABSTRACT...
Read More

The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials

Front Immunol. 2026 Jan 6;16:1744165. doi: 10.3389/fimmu.2025.1744165. eCollection 2025. ABSTRACT...
Read More

Temporal trends in progression risk in smoldering myeloma: a systematic review

EClinicalMedicine. 2026 Jan 8;91:103750. doi: 10.1016/j.eclinm.2025.103750. eCollection 2026 Jan....
Read More

Email

info@myeloma360.com

bahisliongalabet